That was higher than the 0.3% gain during the third quarter. Target posted a 2% gain in the second quarter and a 3.7% drop in ...
Target’s profit will be pressured in the first quarter due to tariff uncertainty and bad weather, but will then see ...
The company also cut its long-term outlook at its New York City investor day, much to the frustration of analysts. Target ...
Scotiabank initiated coverage of Gain Therapeutics (GANX) with an Outperform rating and $12 price target Gain’s GT-02287 is potential blockbuster drug in Phase 1b that could be a disease-modifyi ...
Target plans to drive $15B in sales growth by 2030 by expanding product categories, digital marketplace, owned brands, stores ...
Target (TGT) may have to do a lot more this year ... 1.18% estimate (Last year comparable sales fell 4.4%; Walmart US reported a 4.6% gain in its fourth quarter.) ...
Roth Capital raised Gain Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Roth Mkm reaffirmed a “buy” rating and issued a $7.00 target price on shares of Gain ...